E-viri
Recenzirano
Odprti dostop
-
Wheeler, David A.; Takebe, Naoko; Hinoue, Toshinori; Hoadley, Katherine A.; Cardenas, Maria F.; Hamilton, Alina M.; Laird, Peter W.; Wang, Linghua; Johnson, Adrienne; Dewal, Ninad; Miller, Vincent; Piñeyro, David; Castro de Moura, Manuel; Esteller, Manel; Shen, Hui; Zenklusen, Jean Claude; Tarnuzzer, Roy; McShane, Lisa M.; Tricoli, James V.; Williams, Paul M.; Lubensky, Irina; O'Sullivan-Coyne, Geraldine; Kohn, Elise C.; Little, Richard F.; White, Jeffrey; Malik, Shakun; Harris, Lyndsay; Weil, Carol; Chen, Alice P.; Karlovich, Chris; Rodgers, Brian; Shankar, Lalitha; Jacobs, Paula; Nolan, Tracy; Hu, Jianhong; Muzny, Donna M.; Doddapaneni, Harshavardhan; Korchina, Viktoriya; Gastier-Foster, Julie; Bowen, Jay; Leraas, Kristen; Edmondson, Elijah F.; Doroshow, James H.; Conley, Barbara A.; Ivy, S. Percy; Staudt, Louis M.
Cancer cell, 01/2021, Letnik: 39, Številka: 1Journal Article
A small fraction of cancer patients with advanced disease survive significantly longer than patients with clinically comparable tumors. Molecular mechanisms for exceptional responses to therapy have been identified by genomic analysis of tumor biopsies from individual patients. Here, we analyzed tumor biopsies from an unbiased cohort of 111 exceptional responder patients using multiple platforms to profile genetic and epigenetic aberrations as well as the tumor microenvironment. Integrative analysis uncovered plausible mechanisms for the therapeutic response in nearly a quarter of the patients. The mechanisms were assigned to four broad categories—DNA damage response, intracellular signaling, immune engagement, and genetic alterations characteristic of favorable prognosis—with many tumors falling into multiple categories. These analyses revealed synthetic lethal relationships that may be exploited therapeutically and rare genetic lesions that favor therapeutic success, while also providing a wealth of testable hypotheses regarding oncogenic mechanisms that may influence the response to cancer therapy. Display omitted •Genomics of 110 patients with exceptional response to therapy profiled•Plausible molecular mechanisms related to therapy identified in ∼23% of cases•Proposed mechanisms involve DNA damage, signaling, and the immune response•Synthetic lethality with temozolomide in tumors with a defective DNA damage response Profiling multi-platform genomics of 110 cancer patients with an exceptional therapeutic response, Wheeler et al. identify putative molecular mechanisms explaining this survival phenotype in ∼23% of cases. Therapeutic success is related to rare molecular features of responding tumors, exploiting synthetic lethality and oncogene addiction.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.